162 related articles for article (PubMed ID: 31468506)
1. A journey through infectious risk associated with ruxolitinib.
Sant'Antonio E; Bonifacio M; Breccia M; Rumi E
Br J Haematol; 2019 Nov; 187(3):286-295. PubMed ID: 31468506
[TBL] [Abstract][Full Text] [Related]
2. The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis.
Samuelson BT; Vesely SK; Chai-Adisaksopha C; Scott BL; Crowther M; Garcia D
Blood Coagul Fibrinolysis; 2016 Sep; 27(6):648-52. PubMed ID: 26569516
[TBL] [Abstract][Full Text] [Related]
3. [Hematologic Malignancies/Pediatric Malignancies. I. Ruxolitinib Therapy for Myelofibrosis and Polycythemia Vera].
Komatsu N
Gan To Kagaku Ryoho; 2016 May; 43(5):530-4. PubMed ID: 27344680
[No Abstract] [Full Text] [Related]
4. Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera.
Lescuyer S; Ledoux MP; Gravier S; Natarajan-Amé S; Duval C; Maloisel F; Mauvieux L; Toussaint E; Fornecker LM; Herbrecht R
Int J Infect Dis; 2019 Mar; 80():134-136. PubMed ID: 30639623
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib Enhances Platelet Production in Patients With Thrombocytopenic Myelofibrosis.
Grunwald MR; Spivak JL
J Clin Oncol; 2016 Feb; 34(5):e38-40. PubMed ID: 24958831
[No Abstract] [Full Text] [Related]
6. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N
Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854
[TBL] [Abstract][Full Text] [Related]
7. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Bryan JC; Verstovsek S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
[TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge.
Palandri F; Polverelli N; Catani L; Vianelli N
Ann Hematol; 2015 Mar; 94(3):519-20. PubMed ID: 25172457
[No Abstract] [Full Text] [Related]
9. ruxolitinib (JAKAVI°) and polycythaemia vera Inconclusive evaluation.
Prescrire Int; 2016 Oct; 25(175):229-231. PubMed ID: 30645821
[TBL] [Abstract][Full Text] [Related]
10. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
Nazha A; Gerds AT
Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864
[TBL] [Abstract][Full Text] [Related]
11. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.
Passamonti F; Griesshammer M; Palandri F; Egyed M; Benevolo G; Devos T; Callum J; Vannucchi AM; Sivgin S; Bensasson C; Khan M; Mounedji N; Saydam G
Lancet Oncol; 2017 Jan; 18(1):88-99. PubMed ID: 27916398
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).
Mascarenhas J; Marcellino BK; Lu M; Kremyanskaya M; Fabris F; Sandy L; Mehrotra M; Houldsworth J; Najfeld V; El Jamal S; Petersen B; Moshier E; Hoffman R
Leuk Res; 2020 Jan; 88():106272. PubMed ID: 31778911
[TBL] [Abstract][Full Text] [Related]
13. Emerging treatments for classical myeloproliferative neoplasms.
Vannucchi AM; Harrison CN
Blood; 2017 Feb; 129(6):693-703. PubMed ID: 28028027
[TBL] [Abstract][Full Text] [Related]
14. Isolated Nodal TBC Reactivation in a Patient with Post-Thrombocythemia Myelofibrosis Treated with Ruxolitinib: Case Report and Review of the Literature.
Santoro M; Rotolo C; Accurso V; Morreale I; Mancuso S; Siragusa S
Chemotherapy; 2021; 66(3):87-91. PubMed ID: 33784668
[TBL] [Abstract][Full Text] [Related]
15. Elevation of the Hepatitis B Virus DNA during the Treatment of Polycythemia Vera with the JAK Kinase Inhibitor Ruxolitinib.
Kirito K; Sakamoto M; Enomoto N
Intern Med; 2016; 55(10):1341-4. PubMed ID: 27181544
[TBL] [Abstract][Full Text] [Related]
16. Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis.
Koshiishi M; Sueki Y; Kawashima I; Nakajima K; Mitsumori T; Kirito K
Intern Med; 2017 Sep; 56(17):2335-2338. PubMed ID: 28794380
[TBL] [Abstract][Full Text] [Related]
17. Disseminated blastomycosis in a patient with polycythemia vera on ruxolitinib.
Zeitler K; Jariwala R; Alrabaa S; Sriaroon C
BMJ Case Rep; 2021 Nov; 14(11):. PubMed ID: 34725058
[TBL] [Abstract][Full Text] [Related]
18. Infections associated with ruxolitinib: study in the French Pharmacovigilance database.
Sylvine P; Thomas S; Pirayeh E;
Ann Hematol; 2018 May; 97(5):913-914. PubMed ID: 29340760
[No Abstract] [Full Text] [Related]
19. Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.
Mikkelsen SU; Kjaer L; Bjørn ME; Knudsen TA; Sørensen AL; Andersen CBL; Bjerrum OW; Brochmann N; Fassi DE; Kruse TA; Larsen TS; Mourits-Andersen HT; Nielsen CH; Pallisgaard N; Thomassen M; Skov V; Hasselbalch HC
Cancer Med; 2018 Aug; 7(8):3571-3581. PubMed ID: 29932310
[TBL] [Abstract][Full Text] [Related]
20. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]